2023-07-12T12:01:23-04:00 2022-12-31 382706146 YEO & YEO PC 1450 EISENHOWER PLACE ANN ARBOR MI 481083283 990 2022-01-01 382117115 EVERSIGHT EVER 8002477250 3985 RESEARCH PARK DRIVE ANN ARBOR MI 48108 DIANE HOLLINGSWORTH PRESIDENT & CEO 8002477250 2023-07-07 true DIANE HOLLINGSWORTH 999009999 true BRIAN R DIXON P01321580 7347691331 2023-07-07 2022 2023-04-26 12:10:37Z DIANE HOLLINGSWORTH 3985 RESEARCH PARK DR ANN ARBOR MI 48108 30078254 false X WWW.EVERSIGHTVISION.ORG X 1986 MI EVERSIGHT IS A 501(C)3 NONPROFIT ORGANIZATION WITH THE MISSION TO RESTORE SIGHT AND PREVENT BLINDNESS THROUGH THE HEALING POWER OF DONATION, TRANSPLANTATION AND RESEARCH. THE EVERSIGHT NETWORK IS RESPONSIBLE FOR RECOVERING, EVALUATING AND PROVIDING HUMAN EYE TISSUE FOR TRANSPLANTATION; ADVANCING RESEARCH INTO THE CAUSES AND CURES OF BLINDING EYE CONDITIONS; PROMOTING DONATION AWARENESS THROUGH PUBLIC AND PROFESSIONAL EDUCATION; AND PROVIDING HUMANITARIAN AID TO PEOPLE AROUND THE WORLD IN NEED OF CORNEAL TRANSPLANTATION. FOUNDED IN 1947, EVERSIGHT MAINTAINS ITS COMMITMENT TO EXCELLENCE AS AN ACCREDITED MEMBER OF THE EYE BANK ASSOCIATION OF AMERICA (EBAA) AND BY MEETING THE HIGHEST QUALITY STANDARDS SET BY THE U.S. FOOD AND DRUG ADMINISTRATION. THE NONPROFIT OPERATES 24/7/365 IN CONNECTICUT, ILLINOIS, MICHIGAN, NEW JERSEY, OHIO AND SOUTH KOREA, AND COLLABORATES WITH SURGEONS, RESEARCHERS, ACADEMIC MEDICAL CENTERS AND EYE BANKS ACROSS THE UNITED STATES AND ABROAD. EVERSIGHT WORKS WITH THE 11 11 188 109 0 3627186 864304 23990620 24444041 575205 134853 1659 44903 28194670 25488101 0 0 12282882 12646438 0 516385 11352744 11369600 23635626 24016038 4559044 1472063 41315497 41527985 21946040 22776198 19369457 18751787 X EVERSIGHT'S MISSION IS TO RESTORE SIGHT AND PREVENT BLINDNESS THROUGH THE HEALING POWER OF DONATION, TRANSPLANTATION AND RESEARCH. BLINDING EYE DISEASES AFFECT 80 MILLION AMERICANS. THAT MEANS MILLIONS OF PEOPLE CANNOT SEE THEIR LOVED ONES, DRIVE TO WORK OR READ THE NEWSPAPER ON A SUNDAY MORNING. THEIR VISION LOSS RESULTS IN AN ECONOMIC IMPACT OF 51.4 BILLION EVERY YEAR IN THE UNITED STATES ALONE. EVERSIGHT ENVISIONS A WORLD WITHOUT BLINDNESS-A WORLD WHERE ALL MOTHERS CAN SEE THEIR CHILDREN AND ALL CHILDREN CAN GROW UP TO LEAD INDEPENDENT, PRODUCTIVE LIVES THROUGH THE GIFT OF SIGHT. TO MAKE VISION A REALITY FOR ALL, EVERSIGHT CONTINUOUSLY WORKS TO EXPAND ITS REACH, CONNECT MORE EFFECTIVELY WITH COMMUNITIES IN NEED AND PROVIDE THE GIFT OF SIGHT TO EVERYONE. false false 16971336 24368324 RESORING SIGHT IN 2022, EVERSIGHT CELEBRATED ITS 75TH ANNIVERSARY. WE OVERCAME SEVERAL UNFORESEEN CHALLENGES THIS YEAR AND CONTINUED TO MEET THE TISSUE DEMANDS OF SURGEONS IN THE U.S. AND BEYOND. GLOBALLY, WE CONTINUE TO TAKE MEANINGFUL STEPS TOWARD TRANSFORMING THE FUTURE OF VISION CARE BY SUPPORTING SUSTAINABLE EYE BANKING INFRASTRUCTURE AND PROVIDING PRICELESS CLINICAL EDUCATION. IN 2022, EVERSIGHT PROVIDED THE GIFT OF SIGHT TO MORE THAN 6,500 PEOPLE ACROSS THE UNITED STATES AND AROUND THE WORLD. EVERSIGHT'S WORK BEGAN IN 1947 WITH THE ESTABLISHMENT OF THE FOURTH EYE BANK IN THE UNITED STATES, THEN KNOWN AS THE ILLINOIS EYE-BANK. OVER TIME, NONPROFIT EYE BANKS WERE ESTABLISHED IN EVERY STATE TO MEET THE CRITICAL DEMAND FOR CORNEAL TISSUE TO TREAT PREVENTABLE BLINDNESS. IN 1985, THE ILLINOIS EYE-BANK AND MICHIGAN EYE-BANK FORMED A PARTNERSHIP ONE THAT WOULD EARN A REPUTATION FOR CLINICAL EXCELLENCE MADE POSSIBLE BY SOME OF THE FINEST MEDICAL DIRECTORS, STAFF AND BOARD MEMBERS IN THE EYE BANKING FIELD. THE SUCCESS OF THE ORGANIZATION ATTRACTED AFFILIATIONS WITH OTHER REGIONAL EYE BANKS FORMING ONE OF THE LARGEST NETWORKS OF EYE BANKS IN THE U.S. IN 2015, THE NETWORK BECAME KNOWN AS EVERSIGHT, ALL WORKING TOGETHER AS A UNIFIED OPERATION TO DELIVER THE HIGHEST QUALITY SERVICES TO SURGEONS AND THEIR PATIENTS AND TO CONTINUE TO GROW OUR IMPACT AROUND THE WORLD. IN 2022, EVERSIGHT FACED AN UNPRECEDENTED CHALLENGE IN THE FORM OF A CORNEA STORAGE MEDIA SHORTAGE. CORNEA STORAGE MEDIA IS THE SOLUTION IN WHICH CORNEAS ARE STORED BETWEEN RECOVERY AND TRANSPLANTATION. THIS SHORTAGE IMPACTS EVERSIGHT'S ABILITY TO STORE REQUESTED TISSUE. EVERSIGHT PRIORITIZES THE PLACEMENT OF DONATED TISSUE DOMESTICALLY. AS SUCH, THIS STORAGE MEDIA SHORTAGE IMPACTED OUR ABILITY TO PLACE TISSUE INTERNATIONALLY, FOR RESEARCH AND FOR EDUCATION. TO ADDRESS THIS CHALLENGE, EVERSIGHT STAFF COLLABORATED WITH DOMESTIC EYE BANK PARTNERS TO SHARE STORAGE MEDIA AND ENSURE THE PROPER SUPPLY OF DONATED CORNEA TISSUES. THESE PARTNERSHIPS ALLOWED US TO MEET THE NEED FOR CORNEA TISSUE IN THE U.S. AND ABROAD. EVERSIGHT PROVIDED 11,676 TISSUES FOR TRANSPLANTATION, RESEARCH AND EDUCATION GLOBALLY IN 2022. WE WORKED OR PLACED TISSUE WITH PHYSICIANS AND RESEARCHERS IN 32 COUNTRIES AND FACILITATED TRAINING FOR OVER 550 CLINICIANS. TOGETHER WITH ALL OUR PARTNERS-ADVOCATES, DONOR FAMILIES, TRANSPLANT RECIPIENTS, SURGEONS, LIONS, FELLOW EYE BANKS, HEALTHCARE LEADERS, PHILANTHROPIC SUPPORTERS AND MANY OTHERS-WE WERE ABLE TO MAKE VISION A REALITY FOR MORE PEOPLE WORLDWIDE. 161164 34000 FINDING A CURE IN THE PURSUIT OF ELIMINATING BLINDING EYE DISEASES, EVERSIGHT ESTABLISHED THE EVERSIGHT CENTER FOR VISION AND EYE BANKING RESEARCH IN CLEVELAND, OHIO, TO PROVIDE LEADING OPHTHALMOLOGY RESEARCHERS WITH THE RESOURCES THEY NEED TO FIND CURES AND TREATMENTS FOR EYE DISEASES SUCH AS AGE-RELATED MACULAR DEGENERATION, DIABETIC RETINOPATHY AND GLAUCOMA. EVERSIGHT PROVIDED MORE THAN 3,900 TISSUES FOR RESEARCH AND EDUCATION PURPOSES IN 2022. OUR IN-HOUSE RESEARCH TEAM ALSO PROVIDED EVERSIGHT PARTNERS WITH VALUABLE RESEARCH AND DEVELOPMENT SERVICES, AND PIONEERED NEW EYE BANKING PRACTICES. SINCE THE ESTABLISHMENT OF THE CENTER FOR VISION AND EYE BANKING RESEARCH IN 2019, EVERSIGHT HAS PUBLISHED 20 SCIENTIFIC PUBLICATIONS IN PEER REVIEWED SCIENTIFIC JOURNALS. NOTABLY, IN 2022, EVERSIGHT'S RESEARCH TEAM PUBLISHED THREE HIGHLY SIGNIFICANT AND IMPACTFUL RESEARCH ARTICLES. THE FIRST FOCUSED ON UNDERSTANDING THE EFFECT OF INCREASING POVIDONE-IODINE EXPOSURE ON CORNEAL TISSUE AND ITS IMPACT ON THE GROWTH OF MICROORGANISMS. THIS RESEARCH CONDUCTED BY EVERSIGHT DEVELOPED AN INNOVATIVE PROTOCOL FOR ALL OTHER EYE BANKS TO FOLLOW THAT CAN IMPROVE OUTCOMES FOR CORNEAL TRANSPLANT RECIPIENTS AND REDUCE RISK OF INFECTION AFTER CORNEAL TRANSPLANTATION. THE SECOND STUDY, PUBLISHED IN THE PRESTIGIOUS AND HIGH-IMPACT FACTOR JOURNAL, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, DISCOVERED THE IMPORTANT BIOLOGICAL PROCESS OF VISUAL PHOTOTRANSDUCTION IN THE RETINA COLLECTED FROM CADAVERIC HUMAN TISSUE PROCURED AND PROCESSED BY EVERSIGHT. THIS STUDY ALLOWED EVERSIGHT'S RESEARCH TEAM TO GAIN ADDITIONAL RECOGNITION AMONG OUR PEERS AS A LEADING RESEARCH-DRIVEN EYE BANK. THIS WORK SERVES AS AN EXAMPLE TO THE OPHTHALMIC RESEARCH INDUSTRY THAT CADAVERIC OCULAR TISSUES PLAY AN IMPORTANT ROLE IN UNDERSTANDING THE PHYSIOLOGY AND PATHOLOGY OF VARIOUS OPHTHALMIC DISEASES AND THE VISUAL PHOTO- TRANSDUCTION PROCESS. THE FINAL STUDY REVEALED HISTOPATHOLOGICAL ASSESSMENT OF RETINAL BLOOD VESSEL CHANGES IN A PATIENT WITH COVID-19, PROVIDING A DEEPER UNDERSTANDING OF THE IMPACT OF COVID-19 ON THE RETINA. THIS STUDY WAS PUBLISHED IN THE JOURNAL, GRAEFE'S ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY. EVERSIGHT HAS A LONGSTANDING TRACK RECORD OF RESEARCH AND DEVELOPMENT, HAVING AWARDING MORE THAN 4 MILLION IN GRANTS TO DATE THAT STIMULATE PIONEERING CLINICAL AND BASIC SCIENCE RESEARCH AIMING TO DEVELOP NEW WAYS TO RESTORE SIGHT, PREVENT BLINDNESS AND ULTIMATELY HELP PATIENTS LIVE LIFE TO THE FULLEST. SINCE 1980, OUR EYE & VISION RESEARCH GRANT PROGRAM HAS SUPPORTED RESEARCHERS AT LEADING ACADEMIC MEDICAL INSTITUTIONS INCLUDING HARVARD, TUFTS, CLEVELAND CLINIC, CASE WESTERN RESERVE, UNIVERSITY OF MICHIGAN, NORTHWESTERN AND MORE. BY DESIGN, EVERSIGHT'S GRANT PROGRAM PROVIDES CRITICAL, EARLY-STAGE FUNDING THAT IS INTENDED TO DRIVE FOUNDATIONAL RESEARCH AND DISCOVERY. MANY OF THESE PROJECTS HAVE STIMULATED LARGER-SCALE STUDIES AND WON FURTHER FINANCIAL SUPPORT FROM THE NATIONAL INSTITUTES OF HEALTH. IN THE 2023 FUNDING CYCLE, EVERSIGHT AWARDED GRANTS TO ADVANCE STUDIES TO ENHANCE THE OVERALL UNDERSTANDING OF THE MECHANISMS UNDERLYING DELAYED EPITHELIAL WOUND HEALING IN DIABETIC CORNEAS; CREATE SAFER PROCEDURES FOR SUCCESSFUL CORNEAL TRANSPLANTS; ELUCIDATE THE POTENCY OF NETRIN-4 TO INDUCE NEURONAL GROWTH, ELONGATION AND BRANCHING; AND ESTABLISH THE FOUNDATIONS FOR FUTURE STUDIES TO DEFINE THE ROLES OF POLYQ PROTEINS IN THE HUMAN EYE. THESE INVESTIGATIONS ARE LED BY RESEARCHERS AT WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE, UNIVERSITY OF MICHIGAN KELLOGG EYE CENTER, CASE WESTERN RESERVE UNIVERSITY DEPARTMENT OF OPHTHALMOLOGY & VISUAL SCIENCES, AND UNIVERSITY OF ILLINOIS-CHICAGO COLLEGE OF MEDICINE. EACH YEAR, RECIPIENTS ARE SELECTED BY AN INDEPENDENT REVIEW PANEL OF ACADEMIC RESEARCHERS AND OPHTHALMOLOGISTS. THIS DISTINGUISHED PANEL AWARDS PROPOSALS THAT ENCOURAGE MEANINGFUL SCIENTIFIC INQUISITION AND ALIGN WITH EVERSIGHT'S MISSION TO RESTORE SIGHT AND PREVENT BLINDNESS THROUGH THE HEALING POWER OF DONATION, TRANSPLANTATION AND RESEARCH. 1226217 41717 SUSTAINABLE INTERNATIONAL IMPACT IN 2022, EVERSIGHT PROVIDED TISSUE OR WORKED WITH SURGEONS IN 32 COUNTRIES TO PROVIDE THE GIFT OF SIGHT. EVERSIGHT IS FOCUSED ON MEETING THE HUMANITARIAN NEED FOR CORNEA TISSUES IN COUNTRIES WHERE SIGHT-RESTORING CORNEAL TRANSPLANT PROCEDURES WOULD OTHERWISE BE COMPLETELY UNAVAILABLE. THE BENEFICIARIES OF OUR SURGICAL TISSUE PROVISION AND COMMUNITY EYE BANK DEVELOPMENT INITIATIVES INCLUDE THE HUNDREDS OF THOUSANDS OF PEOPLE WHO SUFFER FROM EYE INJURIES AND BLINDING EYE DISEASES THAT CAN BE TREATED THROUGH CORNEAL TRANSPLANTATION, ALONG WITH THEIR FAMILIES AND LOCAL COMMUNITIES. ACCORDING TO THE WORLD HEALTH ORGANIZATION, EVERY DOLLAR SPENT ON IMPROVING EYE HEALTH IN UNDERDEVELOPED AREAS GENERATES A FOUR-FOLD RETURN ON INVESTMENT. TO ADDRESS SYSTEMIC UNMET NEED, EVERSIGHT ACTIVELY WORKS WITH MEDICAL PROFESSIONALS, GOVERNMENTS, VISION HEALTH ORGANIZATIONS AND OTHER NGOS IN REGIONS LACKING EYE BANKS AND INFRASTRUCTURE, INCLUDING THE MIDDLE EAST, PAKISTAN AND SOUTH KOREA. WITH PROVEN EYE BANKING AND TECHNICAL TRAINING PRACTICES-AND HAVING PLAYED A PART IN THE ELIMINATION OF THE U.S. CORNEA TRANSPLANT WAITING LIST-EVERSIGHT IS UNIQUELY QUALIFIED TO WORK WITH COUNTRIES LACKING TRANSPLANT PROGRAMS TO HELP THEM ESTABLISH NATIONAL NETWORKS FOR EYE BANKING AND CORNEA DONATION WITH CULTURALLY APPROPRIATE DONATION MODELS AND STATE-OF-THE-ART CLINICAL CAPABILITIES. NINETY PERCENT OF VISION-IMPAIRED PEOPLE LIVE IN LOW- AND MIDDLE- INCOME COUNTRIES. IN 2022, EVERSIGHT AND THE DEPARTMENT OF HEALTH - ABU DHABI (DOH), THE REGULATOR OF THE HEALTHCARE SECTOR IN THE EMIRATE, ANNOUNCED A PARTNERSHIP TO ESTABLISH THE FIRST EYE AND TISSUE BANK IN THE UNITED ARAB EMIRATES (UAE). THE PARTNERSHIP WAS FORMALIZED AT THE RECENT INTERNATIONAL CONFERENCE FOR INITIATIVES ON ORGAN AND TISSUE DONATION AND TRANSPLANTATION IN ABU DHABI. EVERSIGHT WILL HANDLE THE DEVELOPMENT AND IMPLEMENTATION OF COMPREHENSIVE MEDICAL STANDARDS, QUALITY ASSURANCE PROTOCOLS AND STANDARD OPERATING PROCEDURES IN COMPLIANCE WITH ALL LAWS AND REGULATIONS OF THE UAE AND IN ACCORDANCE WITH EYE BANKING BEST PRACTICES. THE DOH WILL BE RESPONSIBLE FOR OBTAINING ALL NECESSARY APPROVALS FOR THE ESTABLISHMENT AND OPERATION OF THE EYE AND TISSUE BANK, SERVING AS AN IMPORTER FOR CORNEAS AND OTHER EYE- RELATED TISSUES INTO THE REGION AND WORKING TO INTEGRATE THE EYE/TISSUE BANKING PROGRAM WITH THE UAE NATIONAL PROGRAM FOR ORGAN DONATION. THIS INITIATIVE WILL ALSO STRENGTHEN MUTUAL COLLABORATION IN ACTIVITIES RELATED TO KNOWLEDGE SHARING, HUMAN CAPABILITY BUILDING AND CLINICAL RESEARCH. GLOBALLY, AN ESTIMATED 2.2 BILLION PEOPLE ARE IMPACTED BY BLINDNESS AND VISUAL IMPAIRMENT. APPROXIMATELY ONE BILLION OF THESE INDIVIDUALS ARE COPING WITH BLINDNESS OR VISUAL IMPAIRMENT THAT CAN BE CHARACTERIZED AS PREVENTABLE OR NOT SUFFICIENTLY ADDRESSED. VISION LOSS RESULTS IN SUBSTANTIAL ECONOMIC IMPACT WORLDWIDE DUE TO THE INABILITY OF PEOPLE WHO ARE VISION IMPAIRED TO CONTRIBUTE TO THEIR FULLEST IN THEIR COMMUNITIES. EVERSIGHT ENVISIONS A WORLD WITHOUT BLINDNESS-A WORLD WHERE ALL PEOPLE IN EVERY COMMUNITY CAN LEAD INDEPENDENT, PRODUCTIVE LIVES THROUGH THE GIFT OF SIGHT. WHILE PROVIDING FOR IMMEDIATE GLOBAL CORNEA TRANSPLANT NEEDS WITH U.S. DONOR TISSUE, EVERSIGHT CONTINUES TO ADDRESS THE GLOBAL BURDEN BY EMPOWERING INTERNATIONAL COMMUNITIES TO TAKE MEANINGFUL, SUSTAINABLE STEPS EVERY DAY TO MAKE VISION A REALITY FOR ALL. 18358717 true true false false false false false false false true true false false true true false false true false false false false false false true false false false false true false false false false false false false false true false false false false true true true false false true 27 0 188 true false false false false false true true false false false false false false X 11 11 false false false false false false false true true false false true true true true true true true true false MI IL X JULIE COLLINS 7347802119 3985 RESEARCH PARK DR ANN ARBOR MI 48108 MICHAEL O'KEEFE COO 50.00 X 206161 0 54373 JULIE COLLINS CFO 50.00 7.50 X 208830 0 54373 MICHAEL TITUS VP CLINICAL 50.00 X 181082 0 54043 DIANE HOLLINGSWORTH PRESIDENT & 50.00 X 254972 0 62327 BRET HOPMAN VP MARKETING 50.00 X 151755 0 45925 PATTY JO HERNDON CHAIR 1.00 X X 0 0 0 KATHY L ZELENOCK VICE CHAIR 1.00 X X 0 0 0 DANIELLE E D'ARCY TREASURER 1.00 X X 0 0 0 MAHMOUD N GHAZZI MD PHD SECRETARY 1.00 X X 0 0 0 JAROLD ANDERSON IMM. PAST CH 1.00 X 0 0 0 LORENZO CERVANTES MD DIRECTOR 1.00 X 0 0 0 JONATHAN LASS MD DIRECTOR 1.00 X 0 0 0 SHAHZAD MIAN MD DIRECTOR 1.00 X 0 0 0 CAROL CUNNINGHAM MD DIRECTOR 1.00 X 0 0 0 PROBI KAPUR DIRECTOR 1.00 X 0 0 0 CAROLYN M WELSH DIRECTOR 1.00 X 0 0 0 CATHERINE MCCLORY DIR. COMPLIA 50.00 X 148141 0 30393 INDU VADAKKEPATTATH DATA SCI. & 50.00 X 144969 0 31255 ANDREA MEDRANO DIR. HUMAN R 50.00 X 129153 0 24088 ONKAR SAWANT DIR. RESEARC 50.00 X 151058 0 29680 DIANA BUDZYNSKI CONTROLLER 50.00 X 117117 0 34825 1693238 421282 10 false true false DATA INTUITIONS 2063 LONE WOLF LN CANTON MI 48188 SOFTWARE CONSUL 144848 1 183952 680352 63120 864304 EYE TISSUE FEES 621500 22401703 22401703 INTERCOMPANY CHARGES 621500 1976155 1976155 OTHER REVENUE 621500 66183 66183 24444041 181255 181255 4415128 4461530 -46402 -46402 -46402 173526 183952 128623 44903 44903 25488101 24444041 179756 1273852 260534 1013318 8837386 6363225 2215882 258279 485301 354571 116254 14476 1223315 912690 273140 37485 826584 551833 253055 21696 10306 10306 42675 42675 81101 81101 315717 190492 125225 220430 163876 46371 10183 204802 152867 44402 7533 1385437 1029457 303244 52736 160589 111997 40409 8183 94036 37005 48919 8112 238232 176371 52648 9213 344417 261621 71541 11255 CLINICAL LAB & TECH EXP 7412904 7412904 MISCELLANEOUS 314561 5259 307543 1759 MEMBERSHIP DUES 174578 174578 BUSINESS DEVELOPMENT 126094 30230 94903 961 243721 169207 74514 24016038 18358717 5140936 516385 7492551 2483366 175878 5263160 13500 2743326 2930442 111107 157170 15986576 7881308 8148086 8105268 9769850 9147484 12861199 13441095 41315497 41527985 1843013 1901749 400 400 7549199 7059250 12553428 13814799 21946040 22776198 X 19018819 18606591 350638 145196 19369457 18751787 41315497 41527985 X 1472063 -2089733 X false true X true false X 840439 1197972 672370 3627186 864304 7202271 21135494 21313494 19849742 23990620 24444041 110733391 21975933 22511466 20522112 27617806 25308345 117935662 3750 400130 403880 8766065 3989386 6290645 19046096 8769815 4389516 6290645 19449976 98485686 171063 246808 142247 156491 181255 897864 171063 246808 142247 156491 181255 897864 20345 659 43903 64907 22146996 22758274 20684704 27774956 25533503 118898433 0.82830 0.86570 0.01000 0.01000 X PART III, LINE 12 MISCELLANEOUS 0 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 179087 179087 179087 179087 179087 179087 179087 179087 179087 179087 0.49000 0.51000 false false 7616689 646966 6969723 1258275 578801 679474 1387837 1033856 353981 5723775 5621685 102090 8105268 RECEIVABLE FROM RELATED ENTITY 13344027 DEPOSIT 97068 13441095 PAYABLE TO RELATED ENTITY 13093043 CAPITAL LEASE OBLIGATION 721756 13814799 23445891 -2089733 128624 -1961109 25407000 81101 81101 25488101 24063561 128624 128624 23934937 81101 81101 24016038 SCHEDULE D, PAGE 2, PART V, LINE 4 THE PURPOSE OF THE GIFT OF HOPE EYE AND VISION RESEARCH ENDOWMENT FUND IS TO PROVIDE FOR ANNUAL DISTRIBUTIONS TO SUPPORT EVERSIGHT'S GIFT OF HOPE EYE AND VISIONS RESEARCH PROGRAM. THE PURPOSE OF THE GIFT OF SIGHT CHARITABLE ENDOWMENT FUND IS TO PROVIDE FOR ANNUAL DISTRIBUTIONS TO SUPPORT EVERSIGHT'S PROGRAM WHICH WAIVES TISSUE PROCESSING FEES, OR REDUCES THE FEE FOR PATIENTS WHO ARE UNABLE TO PAY THE FULL AMOUNT. THE PURPOSE OF THE COMMUNITY EDUCATION ENDOWMENT FUND IS TO PROVIDE FOR ANNUAL DISTRIBUTIONS TO SUPPORT EVERSIGHT'S COMMUNITY EDUCATION PROGRAM. SCHEDULE D, PAGE 4, PART XI, LINE 2D SPECIAL EVENTS EXPENSES 128,624 SCHEDULE D, PAGE 4, PART XII, LINE 2D SPECIAL EVENTS EXPENSES 128,624 GALA 259528 128589 130939 67494 34020 NIGHT FOR SIGHT 68914 34457 34457 19430 4468 1 29036 20906 8130 3198 357478 183952 173526 86924 41686 128610 44916 X X X false false false false false false false false false MICHAEL O'KEEFE COO 206161 13624 40749 260534 JULIE COLLINS CFO 208830 13624 40749 263203 MICHAEL TITUS VP CLINICAL SERVICES 181082 12135 41908 235125 DIANE HOLLINGSWORTH PRESIDENT & CEO 254972 16159 46168 317299 BRET HOPMAN VP MARKETING & COMM. 151755 10671 35254 197680 CATHERINE MCCLORY DIR. COMPLIANCE & QC 148141 9061 21332 178534 INDU VADAKKEPATTATH DATA SCI. & APP MGR. 144969 9068 22187 176224 ANDREA MEDRANO DIR. HUMAN RESOURCES 129153 4919 19169 153241 ONKAR SAWANT DIR. RESEARCH/INNOV. 151058 9154 20526 180738 DIANA BUDZYNSKI CONTROLLER 117117 8124 26701 151942 X RAFFLE ITEMS 237 63120 FMV false false false FORM 990 - ORGANIZATION'S MISSION EVERSIGHT'S MISSION IS TO RESTORE SIGHT AND PREVENT BLINDNESS THROUGH THE HEALING POWER OF DONATION, TRANSPLANTATION AND RESEARCH. BLINDING EYE DISEASES AFFECT 80 MILLION AMERICANS. THAT MEANS MILLIONS OF PEOPLE CANNOT SEE THEIR LOVED ONES, DRIVE TO WORK OR READ THE NEWSPAPER ON A SUNDAY MORNING. THEIR VISION LOSS RESULTS IN AN ECONOMIC IMPACT OF 51.4 BILLION EVERY YEAR IN THE UNITED STATES ALONE. EVERSIGHT ENVISIONS A WORLD WITHOUT BLINDNESS-A WORLD WHERE ALL MOTHERS CAN SEE THEIR CHILDREN AND ALL CHILDREN CAN GROW UP TO LEAD INDEPENDENT, PRODUCTIVE LIVES THROUGH THE GIFT OF SIGHT. TO MAKE VISION A REALITY FOR ALL, EVERSIGHT CONTINUOUSLY WORKS TO EXPAND ITS REACH, CONNECT MORE EFFECTIVELY WITH COMMUNITIES IN NEED AND PROVIDE THE GIFT OF SIGHT TO EVERYONE. FORM 990, PAGE 1, PART I, LINE 6 VOLUNTEERS PROVIDE VARIOUS TYPES OF SERVICES, INCLUDING LEADERSHIP, THROUGH OUR BOARD OF DIRECTORS (NATIONAL), AND OUR SERVICE AREA ADVISORY BOARDS. WE ALSO WORK WITH MEMBERS OF THE LIONS CLUB IN MICHIGAN AND THROUGHOUT OUR SERVICE AREAS TO SHARE INFORMATION ABOUT EVERSIGHT AND EYE DONATION, AND TO GATHER INTEL AND FACILITATE MEANINGFUL CONNECTIONS IN THE LOCAL COMMUNITIES WE SERVE. VOLUNTEERS HELP PLAN EVENTS SUCH AS OUR ILLINOIS GIFT OF SIGHT CHARITY EVENT, AND OUR MICHIGAN-BASED GIFT OF SIGHT GOLF CLASSIC, AND SERVE AS REPRESENTATIVES AT DONOR FAMILY GATHERINGS AND OTHER EVENTS. FORM 990, PAGE 2, PART III, LINE 4A RESORING SIGHT IN 2022, EVERSIGHT CELEBRATED ITS 75TH ANNIVERSARY. WE OVERCAME SEVERAL UNFORESEEN CHALLENGES THIS YEAR AND CONTINUED TO MEET THE TISSUE DEMANDS OF SURGEONS IN THE U.S. AND BEYOND. GLOBALLY, WE CONTINUE TO TAKE MEANINGFUL STEPS TOWARD TRANSFORMING THE FUTURE OF VISION CARE BY SUPPORTING SUSTAINABLE EYE BANKING INFRASTRUCTURE AND PROVIDING PRICELESS CLINICAL EDUCATION. IN 2022, EVERSIGHT PROVIDED THE GIFT OF SIGHT TO MORE THAN 6,500 PEOPLE ACROSS THE UNITED STATES AND AROUND THE WORLD. EVERSIGHT'S WORK BEGAN IN 1947 WITH THE ESTABLISHMENT OF THE FOURTH EYE BANK IN THE UNITED STATES, THEN KNOWN AS THE ILLINOIS EYE-BANK. OVER TIME, NONPROFIT EYE BANKS WERE ESTABLISHED IN EVERY STATE TO MEET THE CRITICAL DEMAND FOR CORNEAL TISSUE TO TREAT PREVENTABLE BLINDNESS. IN 1985, THE ILLINOIS EYE-BANK AND MICHIGAN EYE-BANK FORMED A PARTNERSHIP ONE THAT WOULD EARN A REPUTATION FOR CLINICAL EXCELLENCE MADE POSSIBLE BY SOME OF THE FINEST MEDICAL DIRECTORS, STAFF AND BOARD MEMBERS IN THE EYE BANKING FIELD. THE SUCCESS OF THE ORGANIZATION ATTRACTED AFFILIATIONS WITH OTHER REGIONAL EYE BANKS FORMING ONE OF THE LARGEST NETWORKS OF EYE BANKS IN THE U.S. IN 2015, THE NETWORK BECAME KNOWN AS EVERSIGHT, ALL WORKING TOGETHER AS A UNIFIED OPERATION TO DELIVER THE HIGHEST QUALITY SERVICES TO SURGEONS AND THEIR PATIENTS AND TO CONTINUE TO GROW OUR IMPACT AROUND THE WORLD. IN 2022, EVERSIGHT FACED AN UNPRECEDENTED CHALLENGE IN THE FORM OF A CORNEA STORAGE MEDIA SHORTAGE. CORNEA STORAGE MEDIA IS THE SOLUTION IN WHICH CORNEAS ARE STORED BETWEEN RECOVERY AND TRANSPLANTATION. THIS SHORTAGE IMPACTS EVERSIGHT'S ABILITY TO STORE REQUESTED TISSUE. EVERSIGHT PRIORITIZES THE PLACEMENT OF DONATED TISSUE DOMESTICALLY. AS SUCH, THIS STORAGE MEDIA SHORTAGE IMPACTED OUR ABILITY TO PLACE TISSUE INTERNATIONALLY, FOR RESEARCH AND FOR EDUCATION. TO ADDRESS THIS CHALLENGE, EVERSIGHT STAFF COLLABORATED WITH DOMESTIC EYE BANK PARTNERS TO SHARE STORAGE MEDIA AND ENSURE THE PROPER SUPPLY OF DONATED CORNEA TISSUES. THESE PARTNERSHIPS ALLOWED US TO MEET THE NEED FOR CORNEA TISSUE IN THE U.S. AND ABROAD. EVERSIGHT PROVIDED 11,676 TISSUES FOR TRANSPLANTATION, RESEARCH AND EDUCATION GLOBALLY IN 2022. WE WORKED OR PLACED TISSUE WITH PHYSICIANS AND RESEARCHERS IN 32 COUNTRIES AND FACILITATED TRAINING FOR OVER 550 CLINICIANS. TOGETHER WITH ALL OUR PARTNERS-ADVOCATES, DONOR FAMILIES, TRANSPLANT RECIPIENTS, SURGEONS, LIONS, FELLOW EYE BANKS, HEALTHCARE LEADERS, PHILANTHROPIC SUPPORTERS AND MANY OTHERS-WE WERE ABLE TO MAKE VISION A REALITY FOR MORE PEOPLE WORLDWIDE. FORM 990, PAGE 2, PART III, LINE 4B FINDING A CURE IN THE PURSUIT OF ELIMINATING BLINDING EYE DISEASES, EVERSIGHT ESTABLISHED THE EVERSIGHT CENTER FOR VISION AND EYE BANKING RESEARCH IN CLEVELAND, OHIO, TO PROVIDE LEADING OPHTHALMOLOGY RESEARCHERS WITH THE RESOURCES THEY NEED TO FIND CURES AND TREATMENTS FOR EYE DISEASES SUCH AS AGE-RELATED MACULAR DEGENERATION, DIABETIC RETINOPATHY AND GLAUCOMA. EVERSIGHT PROVIDED MORE THAN 3,900 TISSUES FOR RESEARCH AND EDUCATION PURPOSES IN 2022. OUR IN-HOUSE RESEARCH TEAM ALSO PROVIDED EVERSIGHT PARTNERS WITH VALUABLE RESEARCH AND DEVELOPMENT SERVICES, AND PIONEERED NEW EYE BANKING PRACTICES. SINCE THE ESTABLISHMENT OF THE CENTER FOR VISION AND EYE BANKING RESEARCH IN 2019, EVERSIGHT HAS PUBLISHED 20 SCIENTIFIC PUBLICATIONS IN PEER REVIEWED SCIENTIFIC JOURNALS. NOTABLY, IN 2022, EVERSIGHT'S RESEARCH TEAM PUBLISHED THREE HIGHLY SIGNIFICANT AND IMPACTFUL RESEARCH ARTICLES. THE FIRST FOCUSED ON UNDERSTANDING THE EFFECT OF INCREASING POVIDONE-IODINE EXPOSURE ON CORNEAL TISSUE AND ITS IMPACT ON THE GROWTH OF MICROORGANISMS. THIS RESEARCH CONDUCTED BY EVERSIGHT DEVELOPED AN INNOVATIVE PROTOCOL FOR ALL OTHER EYE BANKS TO FOLLOW THAT CAN IMPROVE OUTCOMES FOR CORNEAL TRANSPLANT RECIPIENTS AND REDUCE RISK OF INFECTION AFTER CORNEAL TRANSPLANTATION. THE SECOND STUDY, PUBLISHED IN THE PRESTIGIOUS AND HIGH-IMPACT FACTOR JOURNAL, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, DISCOVERED THE IMPORTANT BIOLOGICAL PROCESS OF VISUAL PHOTOTRANSDUCTION IN THE RETINA COLLECTED FROM CADAVERIC HUMAN TISSUE PROCURED AND PROCESSED BY EVERSIGHT. THIS STUDY ALLOWED EVERSIGHT'S RESEARCH TEAM TO GAIN ADDITIONAL RECOGNITION AMONG OUR PEERS AS A LEADING RESEARCH-DRIVEN EYE BANK. THIS WORK SERVES AS AN EXAMPLE TO THE OPHTHALMIC RESEARCH INDUSTRY THAT CADAVERIC OCULAR TISSUES PLAY AN IMPORTANT ROLE IN UNDERSTANDING THE PHYSIOLOGY AND PATHOLOGY OF VARIOUS OPHTHALMIC DISEASES AND THE VISUAL PHOTO- TRANSDUCTION PROCESS. THE FINAL STUDY REVEALED HISTOPATHOLOGICAL ASSESSMENT OF RETINAL BLOOD VESSEL CHANGES IN A PATIENT WITH COVID-19, PROVIDING A DEEPER UNDERSTANDING OF THE IMPACT OF COVID-19 ON THE RETINA. THIS STUDY WAS PUBLISHED IN THE JOURNAL, GRAEFE'S ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY. EVERSIGHT HAS A LONGSTANDING TRACK RECORD OF RESEARCH AND DEVELOPMENT, HAVING AWARDING MORE THAN 4 MILLION IN GRANTS TO DATE THAT STIMULATE PIONEERING CLINICAL AND BASIC SCIENCE RESEARCH AIMING TO DEVELOP NEW WAYS TO RESTORE SIGHT, PREVENT BLINDNESS AND ULTIMATELY HELP PATIENTS LIVE LIFE TO THE FULLEST. SINCE 1980, OUR EYE & VISION RESEARCH GRANT PROGRAM HAS SUPPORTED RESEARCHERS AT LEADING ACADEMIC MEDICAL INSTITUTIONS INCLUDING HARVARD, TUFTS, CLEVELAND CLINIC, CASE WESTERN RESERVE, UNIVERSITY OF MICHIGAN, NORTHWESTERN AND MORE. BY DESIGN, EVERSIGHT'S GRANT PROGRAM PROVIDES CRITICAL, EARLY-STAGE FUNDING THAT IS INTENDED TO DRIVE FOUNDATIONAL RESEARCH AND DISCOVERY. MANY OF THESE PROJECTS HAVE STIMULATED LARGER-SCALE STUDIES AND WON FURTHER FINANCIAL SUPPORT FROM THE NATIONAL INSTITUTES OF HEALTH. IN THE 2023 FUNDING CYCLE, EVERSIGHT AWARDED GRANTS TO ADVANCE STUDIES TO ENHANCE THE OVERALL UNDERSTANDING OF THE MECHANISMS UNDERLYING DELAYED EPITHELIAL WOUND HEALING IN DIABETIC CORNEAS; CREATE SAFER PROCEDURES FOR SUCCESSFUL CORNEAL TRANSPLANTS; ELUCIDATE THE POTENCY OF NETRIN-4 TO INDUCE NEURONAL GROWTH, ELONGATION AND BRANCHING; AND ESTABLISH THE FOUNDATIONS FOR FUTURE STUDIES TO DEFINE THE ROLES OF POLYQ PROTEINS IN THE HUMAN EYE. THESE INVESTIGATIONS ARE LED BY RESEARCHERS AT WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE, UNIVERSITY OF MICHIGAN KELLOGG EYE CENTER, CASE WESTERN RESERVE UNIVERSITY DEPARTMENT OF OPHTHALMOLOGY & VISUAL SCIENCES, AND UNIVERSITY OF ILLINOIS-CHICAGO COLLEGE OF MEDICINE. EACH YEAR, RECIPIENTS ARE SELECTED BY AN INDEPENDENT REVIEW PANEL OF ACADEMIC RESEARCHERS AND OPHTHALMOLOGISTS. THIS DISTINGUISHED PANEL AWARDS PROPOSALS THAT ENCOURAGE MEANINGFUL SCIENTIFIC INQUISITION AND ALIGN WITH EVERSIGHT'S MISSION TO RESTORE SIGHT AND PREVENT BLINDNESS THROUGH THE HEALING POWER OF DONATION, TRANSPLANTATION AND RESEARCH. FORM 990, PAGE 2, PART III, LINE 4C SUSTAINABLE INTERNATIONAL IMPACT IN 2022, EVERSIGHT PROVIDED TISSUE OR WORKED WITH SURGEONS IN 32 COUNTRIES TO PROVIDE THE GIFT OF SIGHT. EVERSIGHT IS FOCUSED ON MEETING THE HUMANITARIAN NEED FOR CORNEA TISSUES IN COUNTRIES WHERE SIGHT-RESTORING CORNEAL TRANSPLANT PROCEDURES WOULD OTHERWISE BE COMPLETELY UNAVAILABLE. THE BENEFICIARIES OF OUR SURGICAL TISSUE PROVISION AND COMMUNITY EYE BANK DEVELOPMENT INITIATIVES INCLUDE THE HUNDREDS OF THOUSANDS OF PEOPLE WHO SUFFER FROM EYE INJURIES AND BLINDING EYE DISEASES THAT CAN BE TREATED THROUGH CORNEAL TRANSPLANTATION, ALONG WITH THEIR FAMILIES AND LOCAL COMMUNITIES. ACCORDING TO THE WORLD HEALTH ORGANIZATION, EVERY DOLLAR SPENT ON IMPROVING EYE HEALTH IN UNDERDEVELOPED AREAS GENERATES A FOUR-FOLD RETURN ON INVESTMENT. TO ADDRESS SYSTEMIC UNMET NEED, EVERSIGHT ACTIVELY WORKS WITH MEDICAL PROFESSIONALS, GOVERNMENTS, VISION HEALTH ORGANIZATIONS AND OTHER NGOS IN REGIONS LACKING EYE BANKS AND INFRASTRUCTURE, INCLUDING THE MIDDLE EAST, PAKISTAN AND SOUTH KOREA. WITH PROVEN EYE BANKING AND TECHNICAL TRAINING PRACTICES-AND HAVING PLAYED A PART IN THE ELIMINATION OF THE U.S. CORNEA TRANSPLANT WAITING LIST-EVERSIGHT IS UNIQUELY QUALIFIED TO WORK WITH COUNTRIES LACKING TRANSPLANT PROGRAMS TO HELP THEM ESTABLISH NATIONAL NETWORKS FOR EYE BANKING AND CORNEA DONATION WITH CULTURALLY APPROPRIATE DONATION MODELS AND STATE-OF-THE-ART CLINICAL CAPABILITIES. NINETY PERCENT OF VISION-IMPAIRED PEOPLE LIVE IN LOW- AND MIDDLE- INCOME COUNTRIES. IN 2022, EVERSIGHT AND THE DEPARTMENT OF HEALTH - ABU DHABI (DOH), THE REGULATOR OF THE HEALTHCARE SECTOR IN THE EMIRATE, ANNOUNCED A PARTNERSHIP TO ESTABLISH THE FIRST EYE AND TISSUE BANK IN THE UNITED ARAB EMIRATES (UAE). THE PARTNERSHIP WAS FORMALIZED AT THE RECENT INTERNATIONAL CONFERENCE FOR INITIATIVES ON ORGAN AND TISSUE DONATION AND TRANSPLANTATION IN ABU DHABI. EVERSIGHT WILL HANDLE THE DEVELOPMENT AND IMPLEMENTATION OF COMPREHENSIVE MEDICAL STANDARDS, QUALITY ASSURANCE PROTOCOLS AND STANDARD OPERATING PROCEDURES IN COMPLIANCE WITH ALL LAWS AND REGULATIONS OF THE UAE AND IN ACCORDANCE WITH EYE BANKING BEST PRACTICES. THE DOH WILL BE RESPONSIBLE FOR OBTAINING ALL NECESSARY APPROVALS FOR THE ESTABLISHMENT AND OPERATION OF THE EYE AND TISSUE BANK, SERVING AS AN IMPORTER FOR CORNEAS AND OTHER EYE- RELATED TISSUES INTO THE REGION AND WORKING TO INTEGRATE THE EYE/TISSUE BANKING PROGRAM WITH THE UAE NATIONAL PROGRAM FOR ORGAN DONATION. THIS INITIATIVE WILL ALSO STRENGTHEN MUTUAL COLLABORATION IN ACTIVITIES RELATED TO KNOWLEDGE SHARING, HUMAN CAPABILITY BUILDING AND CLINICAL RESEARCH. GLOBALLY, AN ESTIMATED 2.2 BILLION PEOPLE ARE IMPACTED BY BLINDNESS AND VISUAL IMPAIRMENT. APPROXIMATELY ONE BILLION OF THESE INDIVIDUALS ARE COPING WITH BLINDNESS OR VISUAL IMPAIRMENT THAT CAN BE CHARACTERIZED AS PREVENTABLE OR NOT SUFFICIENTLY ADDRESSED. VISION LOSS RESULTS IN SUBSTANTIAL ECONOMIC IMPACT WORLDWIDE DUE TO THE INABILITY OF PEOPLE WHO ARE VISION IMPAIRED TO CONTRIBUTE TO THEIR FULLEST IN THEIR COMMUNITIES. EVERSIGHT ENVISIONS A WORLD WITHOUT BLINDNESS-A WORLD WHERE ALL PEOPLE IN EVERY COMMUNITY CAN LEAD INDEPENDENT, PRODUCTIVE LIVES THROUGH THE GIFT OF SIGHT. WHILE PROVIDING FOR IMMEDIATE GLOBAL CORNEA TRANSPLANT NEEDS WITH U.S. DONOR TISSUE, EVERSIGHT CONTINUES TO ADDRESS THE GLOBAL BURDEN BY EMPOWERING INTERNATIONAL COMMUNITIES TO TAKE MEANINGFUL, SUSTAINABLE STEPS EVERY DAY TO MAKE VISION A REALITY FOR ALL. FORM 990, PAGE 6, PART VI, LINE 11B THE 990 IS REVIEWED BY THE CEO AND CFO PRIOR TO FILING. COMPLETED 990 IS PROVIDED VIA E-MAIL TO ALL BOARD MEMBERS FOR COMMENTS AND QUESTIONS PRIOR TO FILING. FORM 990, PAGE 6, PART VI, LINE 12C THE POLICY IS REVIEWED DURING NEW EMPLOYEE ORIENTATION AND ANNUALLY WITH THE ENTIRE STAFF AND BOARD OF DIRECTORS. ANY POTENTIAL CONFLICTS OF INTEREST ARE REVIEWED BY SENIOR STAFF UPON DISCOVERY. FORM 990, PAGE 6, PART VI, LINE 15A A PERFORMANCE REVIEW IS CONDUCTED BY THE BOARD HR COMMITTEE WITH CEO; MERIT INCREASE IS RECOMMENDED BY THE HR COMMITTEE AND APPROVED BY THE BOARD. THE CEO IS NOT PART OF COMPENSATION DISCUSSION AND CEO DOES NOT PARTICIPATE IN THE SELECTION OF BOARD MEMBERS. THE CEO SALARY IS COMPARED TO SALARIES OF OTHER CEO'S AT PEER ORGANIZATIONS; OTHER EYE BANKS, OPOS, OTHER NONPROFIT ORGANIZATIONS OF SIMILAR SIZE. IN 2016 THE ORGANIZATION ENGAGED THE SERVICES OF AN INDEPENDENT CONSULTANT TO CONDUCT A LEADERSHIP COMPENSATION ANALYSIS. THEIR SOURCE OF SALARY INFORMATION IS THE 990'S ISSUED BY PEER ORGANIZATIONS, MICHIGAN NONPROFIT ASSOCIATION SALARY SURVEY, PUBLISHED BUDGETS, WEB-BASED RESEARCH THROUGH FOIA SOURCES AND INDEPENDENT SALARY SURVEY DATA. FORM 990, PAGE 6, PART VI, LINE 15B PERFORMANCE REVIEW FOR OFFICERS AND KEY EMPLOYEES IS CONDUCTED BY THE EMPLOYEES' IMMEDIATE MANAGER; MERIT INCREASES ARE RECOMMENDED BY THE MANAGER AND APPROVED BY THE CEO. SALARIES OF OFFICERS AND KEY EMPLOYEES ARE COMPARED TO SALARIES OF OTHER SIMILAR POSITIONS AT PEER ORGANIZATIONS; OTHER EYE BANKS, OPOS, OTHER NONPROFIT ORGANIZATIONS OF SIMILAR SIZE. A REPORT IS PROVIDED TO THE HR COMMITTEE OF THE BOARD OF DIRECTORS FOR THEIR REVIEW. IN 2016 THE ORGANIZATION ENGAGED THE SERVICES OF AN INDEPENDENT CONSULTANT TO CONDUCT A LEADERSHIP COMPENSATION ANALYSIS. THEIR SOURCE OF SALARY INFORMATION IS THE 990'S ISSUED BY PEER ORGANIZATIONS, MICHIGAN NONPROFIT ASSOCIATION SALARY SURVEY, PUBLISHED BUDGETS, WEB-BASED RESEARCH THROUGH FOIA SOURCES AND INDEPENDENT SALARY SURVEY DATA. FORM 990, PAGE 6, PART VI, LINE 19 GOVERNING DOCUMENTS ARE AVAILABLE UPON REQUEST. FORM 990, PART XI, LINE 9 SPECIAL EVENTS EXPENSES 128,624 SPECIAL EVENTS EXPENSES -128,624 EVERSIGHT INTERNATIONAL 3985 RESEARCH PARK DRIVE ANN ARBOR MI 48108 471671769 EYE BANK MI 3 10 EVERSIGHT EVERSIGHT true EVERSIGHT NEW JERSEY 77 BRANT AVE SUITE 100 CLARK NJ 07066 203345087 EYE BANK NJ 3 7 EVERSIGHT EVERSIGHT true EVERSIGHT MICHIGAN 3985 RESEARCH PARK DRIVE ANN ARBOR MI 48108 273107692 EYE BANK MI 3 7 EVERSIGHT EVERSIGHT true EVERSIGHT ILLINOIS 547 WEST JACKSON BLVD SUITE 600 CHICAGO IL 60661 273107617 EYE BANK IL 3 7 EVERSIGHT EVERSIGHT true MIDWIRE SYSTEMS 3985 RESEARCH PARK DRIVE ANN ARBOR MI 48108 383557111 SOFTWARE MI 3 10 EVERSIGHT EVERSIGHT true EVERSIGHT OHIO 6700 EUCLID AVE SUITE 101 CLEVELAND OH 44103 455111431 EYE BANK OH 3 7 EVERSIGHT EVERSIGHT true EVERSIGHT CONNECTICUT 3985 RESEARCH PARK DRIVE ANN ARBOR MI 48108 475113503 EYE BANK CT 3 7 EVERSIGHT EVERSIGHT true EVERSIGHT KOREA LLC 145 A 1638 TEHRAN-RO GUMCHEONGU SEOUL GUMCHEON-GU SEOUL KS EYE BANK KS EVER INT EVERSIGHT INTERNATIONAL C CORP false false false false false false false false false false false false true false false true false false false false EVERSIGHT INTERNATIONAL 274622 O 514555 COST EVERSIGHT INTERNATIONAL 231250 L 1461600 COST